Editor-in-Chief: V.Susan Carroll, MS, RN-BC
ISSN: 0888-0395
Online ISSN: 1945-2810
Frequency: 6 issues per year
Impact Factor: .907
From the Editor
Summer has flown by and for many of us (or our children), school will start soon. This is a great time to think about writing ... JNN is always looking for great manuscripts and we are currently blessed to have many in our queue. Some of our sister journals are not quite as fortunate and are very actively seeking manuscripts. The journal Home Health Nurse would welcome papers that address the basics related to Parkinson disease, seizure disorders, dementia, MS and stroke with a home-care focus. Think about starting your writing portfolio by creating a manuscript for our nurse colleagues. Queries can be sent to HHNEditor@gmail.com A free resource is available for would-be authors to help begin or complete a manuscript. Log on to NurseAuthorEditor.com and register. This journal publishes quarterly and has an extensive writing-related archive available. JNN continues to look for reviewers who are pediatric neuroscience practitioners. You can email me if interested. Keep in mind we award CE hours for reviewing (free!!)
Featured Supplement

JNN December 2013 Supplement

This supplement was developed with the support of Genzyme, a Sanofi company.


Current Issue Highlights


LWW iPad journals users: Not all titles are currently compatible with iOS8. Please see the list of iOS8 compatible titles before updating your iPad to iO8. List updated daily.


American Association of Neuroscience Nurses Official Journal of
American Association of Neuroscience Nurses

To receive access to the online journal, association members must log-in through the AANN website in the members-only area. Please click below:

American Association of Neuroscience Nurses

In the News
Neurosciences in the news ... The FDA just approved trials to evaluate a drug that targets the chorea experienced by patients with Huntington disease. Very few drugs have been systematically evaluated for use in HD so this provides a ray of hope for patients and their families. The Chicago Tribune recently reported that US stroke incidence has dropped steadily among individuals older than 65. The report cautions that the absence of a decline in incidence among younger patients will remain a problem unless health disparities are addressed. A Finnish study reported that mortality remains a concern in younger patients who experience a stroke. Nearly 1 in 6 teens and adults who survive a stroke before age 50 die over the next decade. The biggest threat to survival was recurrent stroke. The researchers posit that more robust primary and secondary prevention strategies are critical. Patients with intracerebral hemorrhage (ICH) have shown improved outcomes when treated with the oral MS drug fingolomid (Gilenya). In this small trial, scores improved on the NIHSS and Barthel index. The purported mechanism of action is decreasing the inflammatory processes that are a part of ICH.